Abstract

Background: Cataract is a major problem for diabetic patients because it decreases the vision, prevents adequate fundus examination and interferes with the strategy of laser photocoagulation for diabetic retinopathy. Present study was aimed to study effect of single intraoperative intravitreal injection of bevacizumab on central macular thickness in patients with diabetes mellites undergoing phacoemulsification cataract surgery under local anaesthesia, Material and Methods: Present study was prospective interventional observational single centre study conducted in patients above 40 years of age with Diabetes underwent Phacoemulsification cataract surgery under Local anaesthesia, Bevacizumab 0.05 ml (1.25 mg) was injected intravitreal. Results: 30 eyes of 27 patients with PDR were studied. Mean age among the study population was 61.167 ± 8.77333 years. Majority of patients were in the age group of 61-70 yrs. (43.3 %), were male (66.67 %), left eye (66.67 %) & had diabetes for more than 10 years (63.37 %). At day one postoperatively 18 patients had central macular thickness < 250 and in 12 patients it was >250. In < 250µ CMT group 33.33 % cases showed decrease, another 33.33% cases showed no change and remaining 33.33 % cases showed increase in CMT which was <10%. While, in >250µ group 58.4% cases showed increase CMT , Out of which in 41.7% cases the increase was >10%, while 41.7% cases showed decrease in CMT at one month Postoperatively. Conclusion: Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery is a safe and effective way in avoiding new onset maculopathy in diabetic retinopathy patients. It is also effective to treat preexisting CSME and prevent its progression to some extent in few cases.

Description